What’s the current market cap for AbbVie stock?

AbbVie (ABBV) has a market cap of $430bn as of June 26, 2026.

What is the P/E ratio for AbbVie stock?

The price to earnings (P/E) ratio for AbbVie (ABBV) stock is 119.77 as of June 26, 2026.

Does AbbVie stock pay dividends?

Yes, the AbbVie (ABBV) stock pays dividends to shareholders. As of June 26, 2026, the dividend rate is $6.74 and the yield is 2.85%. AbbVie has a payout ratio of 325.12% on a trailing twelve-month basis.

When is the next AbbVie dividend payment date?

The next AbbVie (ABBV) dividend payment is scheduled for August 14, 2026.

What is the beta indicator for AbbVie?

AbbVie (ABBV) has a beta rating of 0.3. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy AbbVie stock | $ABBV Share Price

About AbbVie

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

Ticker

$ABBV

Sector

Health

Primary listing

NYSE

Employees

57,000

Headquarters

North Chicago, United States

Website

www.abbvie.com

AbbVie Metrics

BasicAdvanced

$430bn

119.77

$2.03

0.30

$6.74

2.85%

What the Analysts think about AbbVie

Analyst ratings (Buy, Hold, Sell) for AbbVie stock.

Bulls say / Bears say

AbbVie topped Q1 2026 estimates, with $15.0 billion in net revenue (up 12.4% YoY) driven by Skyrizi and Rinvoq sales, and lifted its full-year adjusted EPS guidance range. (Reuters)

The company raised its 2026 adjusted earnings forecast to as much as $14.28 per share, 12 cents above the prior midpoint, reflecting confidence in its portfolio amid biosimilar headwinds. (Bloomberg)

AbbVie plans to invest $380 million in two new U.S. API manufacturing facilities in Illinois to support production capacity for its neuroscience and obesity pipeline, enhancing supply chain resilience. (Reuters)

Humira revenue continued to erode, with global sales down 38.6% year-over-year to $688 million in Q1 2026, underscoring persistent biosimilar competition. (Reuters)

The FDA declined to approve AbbVie’s experimental wrinkle treatment trenibotE due to manufacturing issues, delaying a potential catalyst for the aesthetics segment until at least 2027. (Reuters)

First-quarter results included a $744 million acquired IPR&D and milestones expense that reduced adjusted EPS by $0.41, highlighting integration costs and margin pressures from recent acquisitions. (SEC)

Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2026.

AbbVie Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

AbbVie Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

AbbVie News

AllArticlesVideos

Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE

Business Wire·2 days ago

AbbVie's $11 Billion Immunology Bet

Forbes·2 days ago

AbbVie's Costly Apogee Acquisition Has Long-Term Upside: Analyst

Benzinga·3 days ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.